Clinical Trials

BreastGastrointestinalGenitourinaryGynecologicThoracic

100 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06925737 2026-04-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07082920 2026-04-13

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

140 enrolled

Prostatic Neoplasms

NCT07319871 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

40 enrolled

Prostatic Neoplasms

NCT07523529 2026-04-13

SELECT-2CAR

BreastCNSGastrointestinalGenitourinaryGynecologic

72 enrolled

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

CNSGastrointestinalGenitourinaryGynecologicSarcoma

595 enrolled

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06056830 2026-04-09

CLARIFY

383 enrolled

Prostatic Neoplasms

NCT06801236 2026-04-09

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

67 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT06970847 2026-04-09

AMPLIFY

220 enrolled

Prostatic Neoplasms

NCT06235151 2026-04-08

Solar-Stage

439 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07047118 2026-04-08

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

134 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07181161 2026-04-08

SEACLIFF

177 enrolled

Prostatic Neoplasms

NCT07517198 2026-04-08

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Margins of Excision, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

599 enrolled

Prostatic Neoplasms

NCT06785636 2026-04-07

P300

252 enrolled

Phase 1 Active not recruiting

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07214961 2026-04-07

ARTISAN

80 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT07424547 2026-04-07

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

BreastGenitourinaryGynecologicThoracic

386 enrolled

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT07492381 2026-04-07

A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer

Phase NA Not yet recruiting

50 enrolled

Prostatic Neoplasms

NCT04582656 2026-04-06

VIOLETTE

Phase NA Completed

76 enrolled

Phase NA Not yet recruiting

Neoplasms, Prostatic Neoplasms

NCT07290998 2026-04-06

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer

12 enrolled